28 July 2021

Christa Sperna Weiland, Erwin van Geenen and Joost Drenth, theme Renal disorders and colleagues published in Lancet Gastroenterology & Hepatology a systematic review and network meta-analysis to determine the most efficacious prophylaxis strategy to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.

Background

Non-steroidal anti-inflammatory drugs (NSAIDs), intravenous fluid, pancreatic stents, or combinations of these have been evaluated in randomised controlled trials (RCTs) for the prevention of post-ERCP pancreatitis, but the comparative efficacy of these treatments remains unclear. Our aim was to do an exploratory network meta-analysis of previous RCTs to systematically compare the direct and indirect evidence and rank NSAIDs, intravenous fluids, pancreatic stents, or combinations of these to determine the most efficacious method of prophylaxis for post-ERCP pancreatitis.

Methods

We searched PubMed, Embase, and the Cochrane Central Register from inception to Nov 15, 2020, for full-text RCTs that evaluated the efficacy of NSAIDs, pancreatic stents, intravenous fluids, or combinations of these for post-ERCP pancreatitis prevention in adult (aged ≥18 years) patients undergoing ERCP. Summary data from intention-to-treat analyses were extracted from published reports. We analysed incidence of post-ERCP pancreatitis across studies using network meta-analysis under the frequentist framework, obtaining pairwise odds ratios (ORs) and 95% CIs. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system for the confidence rating. This study is registered with PROSPERO, CRD42020172606.

Findings

We identified 1503 studies, of which 55 RCTs evaluating 20 interventions in 17 062 patients were included in the network meta-analysis. The mean incidence of post-ERCP pancreatitis in the placebo or active control group was 12.2% (95% CI 11.4–13.0). Normal saline plus rectal indometacin (OR 0.02, 95% CI 0.00–0.40), intramuscular diclofenac 75 mg (0.24, 0.09–0.69), intravenous high-volume Ringer's lactate plus rectal diclofenac 100 mg (0.30, 0.16–0.55), intravenous high-volume Ringer's lactate (0.31, 0.12–0.78), 5–7 Fr pancreatic stents (0.35, 0.26–0.48), rectal diclofenac 100 mg (0.36, 0.25–0.52), 3 Fr pancreatic stents (0.47, 0.26–0.87), and rectal indometacin 100 mg (0.60, 0.50–0.73) were all more efficacious than placebo for preventing post-ERCP pancreatitis in pairwise comparisons. 5–7 Fr pancreatic stents (0.59, 0.41–0.84), intravenous high-volume Ringer's lactate plus rectal diclofenac 100 mg (0.49, 0.26–0.94), intravenous standard-volume normal saline plus rectal indometacin 100 mg (0.04, 0.00–0.66), and rectal diclofenac 100 mg (0.59, 0.40–0.89) were more efficacious than rectal indometacin 100 mg. The GRADE confidence rating was low to moderate for 98.3% of the pairwise comparisons.

Interpretation

This systematic review and network meta-analysis summarises the available literature on NSAIDs, pancreatic stents, intravenous fluids, or combinations of these for prophylaxis of post-ERCP pancreatitis. Rectal diclofenac 100 mg is the best performing rectal NSAID in this network meta-analysis. Combinations of prophylaxis might be more effective, but there is little evidence. These findings help to establish prophylaxis of post-ERCP pancreatitis for future research and practice, and could reduce costs and increase adoption of prophylaxis.

read more

Related news items


TropIQ seeks new mosquito repellents

21 September 2021

TropIQ Health Sciences, a Radboudumc spin-off, has received a 1.3 million USD grant from the Bill & Melinda Gates Foundation to track down new mosquito repellents.

read more

Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path

16 September 2021

The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.

read more

Infections increase risk to develop dementia

16 September 2021

In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.

read more

Young Investigator Award for Alex Garanto

16 September 2021

Alex Garanto has been honored with the 2021 Mary Ann Liebert, Inc. publishers Young Investigator Award

read more

Depressive symptoms during pregnancy affect baby

16 September 2021

Study in Obstetrics & Gynecology shows associations between depression and adverse birth outcomes

read more

ENABLECARES launches a course on entrepreneurship for PhD candidates and postdocs

15 September 2021

Are you thinking about what to do after your PhD? Want to know more about entrepreneurship? This course gives you insight in many aspects of entrepreneurship and research in industry.

read more